Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cilostazol + dexborneol
- Development stage
- Phase 3
- Lead developer
- Nanjing Ningdan New Drug Technology
- Modality
- Small Molecules
- Administration
- Sublingual
01
Overview
Cilostazol + dexborneol is a fixed-dose combination drug formulated as a multi-component tablet, primarily investigated for the treatment of acute ischemic stroke (AIS), especially in patients who have undergone reperfusion therapy for large vessel occlusion. Cilostazol is a phosphodiesterase 3 (PDE3) inhibitor with antiplatelet effects and blood-brain barrier protection, while dexborneol is an anti-inflammatory agent. The combination aims to provide neuroprotective effects by improving microcirculation dysfunction and reducing thrombo-inflammation after AIS. Clinical studies suggest that this dual-action approach may enhance recovery outcomes compared to placebo[2][3][4][6][8].
- Brand names
- Y-6 sublingual tabletsY6 sublingual tabletsY 6 sublingual tablets
- Other names
- cilostazol and dexborneol combination therapycilostazol dexborneol
02
Targets
PDE3B (Phosphodiesterase 3B)PDE3A (Phosphodiesterase 3A)
Beyond the preview
Go deeper on cilostazol + dexborneol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cilostazol + dexborneol.